Skip to main content
. 2013 Oct 10;104(12):1593–1599. doi: 10.1111/cas.12281

Figure 2.

Figure 2

Combination of a poly (ADP‐ribose) poly‐merase (PARP) inhibitor 3‐aminobenzamide (3‐AB) with cisplatin or 5‐fluorouracil (5‐FU) in human esophageal cancer cell lines. (a) Survival of TE11, TE14, and TE15 cells after treatment with either 5 μM cisplatin for 1 h or 3 μM 5‐FU for 24 h, with or without pretreatment with 3 mM (TE14) or 5 mM (TE11 and TE15) 3‐AB for 48 h. (b) Evaluation of the γH2AX focus formation at 24 h after treatment of TE11, TE14, and TE15 cells with either cisplatin or 5‐FU, with or without pretreatment with 3‐AB. (c) DNA (blue) and γH2AX foci (red) were visualized at 24 h after treatment of TE11 cells. Scale bar = 10 μm. (d,e) TE11 cells were treated with either cisplatin or 5‐FU, with or without pretreatment with 3‐AB. Cells with 10 or more foci were counted as positive. At least 200 nuclei were counted for each experiment. The average and SD from at least three experiments are shown.